Actus Biotechnologies, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actus Biotechnologies, Inc.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Convoy Therapeutics Inc.’s SPACE platform for delivering large molecule drugs through the skin is based on a class of peptides that associate with keratin proteins, and the peptides get passed from one to the other until they diffuse across the outer layer of skin. The peptides can be formulated to envelop drug molecules. Convoy is using drugs that are already FDA approved, and because they have not been chemically modified, the FDA will not require additional clinical trials. The company’s first product delivers the immune-modulating drug cyclosporine for the treatment of moderate to severe psoriasis.
Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.
This Month's Profile Group: New Orals, Better Topicals Top Psoriasis Wish List, features profiles of Avexxin, Cellceutix, Convoy Therapeutics, and Creabilis. Plus these Start-Ups Across Health Care: Domain Surgical, Ornim, Protagonist Therapeutics, SpineGuard, and Xcovery.
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Convoy Therapeutics, Inc.